LBR81 schreef op 24 januari 2019 16:25:
2.6.1. Viable T-cells - Orphan - EMEA/H/C/002397
Kiadis Pharma Netherlands B.V.; Adjunctive treatment in haematopoietic stem cell transplantation (HSCT) for a malignant disease
Scope: request by the applicant for a second clock stop extension .
Action: for adoption
Oral Explanation took place on 12.09.2018. List of Outstanding Issues adopted on 14.09.18 and 25.05.2018. List of Questions adopted on 08.09.2017.